BioCentury
ARTICLE | Financial News

RNAi company OliX lists in Korea

July 17, 2018 11:02 PM UTC

OliX Pharmaceuticals Inc. (KOSDAQ:226950) raised KrW43.2 billion ($38.3 million) through the sale of 1.2 million shares at KrW36,000 in an IPO on KRX underwritten by NH Investment & Securities.

Next half, OliX expects to complete a U.K. Phase I trial of OLX10010 to treat hypertrophic scars. The RNA interference therapeutic targets connective tissue growth factor (CTGF)...